# Aprepitant Eases Cannabinoid Hyperemesis Syndrome in Teens > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/aprepitant-eases-cannabinoid-hyperemesis-syndrome-in-teens/ > **Published:** 2026-08-13T07:16:19-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:16:45-04:00 > **Clinical Summary:** Aprepitant offers a new pharmacologic option for cannabinoid hyperemesis syndrome in adolescents. Evidence summary for clinicians. --- ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PediatricsResearchTHCSafetyNeurologyMental HealthDosing Why This Matters [Cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome (CHS) is an increasingly recognized condition in adolescents that can present with severe, intractable nausea and vomiting, and clinicians need effective treatment options beyond standard antiemetics. This study demonstrates that aprepitant, an NK1 receptor antagonist, may provide relief for CHS patients who fail conventional treatments, offering clinicians a pharmacological tool to address this emerging cannabis-related complication. For patients, particularly teenagers, this finding provides an evidence-based treatment option that could reduce hospitalizations and improve [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) while addressing the underlying cannabinoid use. Clinical Summary [Cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome (CHS), characterized by severe cyclic nausea and vomiting triggered by [chronic cannabis use](https://cedclinic.com/cannabis-tolerance-behavioral-models/), is an increasingly recognized clinical problem in adolescent populations as [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) rates rise. This study demonstrates that aprepitant, an FDA-approved neurokinin-1 receptor antagonist commonly used for chemotherapy-induced nausea, effectively alleviates symptoms in teenage patients with CHS, offering a pharmacological alternative to the standard management approach of cannabis cessation alone. The mechanism likely involves aprepitant’s modulation of substance P signaling in the brain’s chemoreceptor trigger zone, which may counteract cannabis-related neurogenic inflammation. This finding is particularly relevant for clinicians treating adolescents who may be unwilling or unable to immediately discontinue [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), as aprepitant provides symptomatic relief while addressing the underlying hyperemetic response. Understanding that CHS can present with severe dehydration and electrolyte abnormalities in younger patients warrants heightened clinical vigilance in this population. Clinicians should consider aprepitant as an adjunctive option when managing CHS in teenagers, particularly when cannabis cessation is not immediately achievable. Dr. Caplan’s Take “We’re seeing preliminary signals that aprepitant, an NK1 receptor antagonist already proven for chemotherapy-induced nausea, may help manage [cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome in adolescents, but this is early work we need to see replicated in larger, controlled trials before making it standard practice for this population.” Clinical Perspective 🤢 While cannabinoid hyperemesis syndrome remains an uncommon but severe presentation in [adolescent cannabis](https://cedclinic.com/cannabis-use-disorder-psychiatric-risk/) users, the potential utility of aprepitant—a neurokinin-1 receptor antagonist already established for chemotherapy-induced nausea—warrants clinical attention given the limited evidence base for treating this condition. The proposed mechanism involving substance P and the antiemetic pathway differs from cannabis’s direct cannabinoid receptor effects, suggesting a potentially rational pharmacologic approach, though the evidence from this work appears preliminary and should be interpreted cautiously in the context of the heterogeneous presentations of CHS and variable [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns among teenagers. Critical confounders include the difficulty isolating cannabis as the sole etiology in adolescents who may use multiple substances, the role of behavioral factors and cessation, and whether aprepitant’s benefit reflects true disease modification or symptom management pending cannabis discontinuation. Clinicians encountering adolescents with rec 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/pediatrics-and-individuals-with-guardians/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Aprepitant%20Eases%20Cannabinoid%20Hyperemesis%20Syndrome%20in%20Teens%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73274)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73274)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Aprepitant%20Eases%20Cannabinoid%20Hyperemesis%20Syndrome%20in%20Teens%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73274)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.medscape.com/viewarticle/aprepitant-eases-cannabinoid-hyperemesis-syndrome-teens-2026a1000roo](https://www.medscape.com/viewarticle/aprepitant-eases-cannabinoid-hyperemesis-syndrome-teens-2026a1000roo) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).